Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that MET Exon 14 (Deletion) status confers therapeutic sensitivity to Capmatinib in patients with Non-Small Cell Lung Cancer.
This statement is based on a regulatory approval from the Health Canada:
TABRECTA (capmatinib tablets) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.